Quick Answer
PAVmed Inc. reported Research And Development Expense of $4.49 million for the year ending 2025.
- PAVmed Inc. showed a decrease of -24.3% in Research And Development Expense from 2024 to 2025.
- This data is from PAVmed Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), PAVmed Inc.'s Research And Development Expense has grown by 818.0%.
- Historical annual values: Fiscal year 2025: $4.49 million | Fiscal year 2024: $5.93 million | Fiscal year 2023: $14.28 million | Fiscal year 2022: $25.34 million | Fiscal year 2021: $19.85 million | Fiscal year 2020: $10.96 million | Fiscal year 2019: $6.63 million | Fiscal year 2018: $4.25 million | Fiscal year 2017: $2.62 million | Fiscal year 2016: $1.72 million | Fiscal year 2015: $489.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: